Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andamertinib With or Without Chemotherapy in Previously Untreated Advanced Non-squamous NSCLC With Atypical EGFR Mutations
NCT07336732Phase 2Recruiting
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of andamertinib in non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd.. Started Mar 2026; status: recruiting.
02
Drugs
andamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07336732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336732.